A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome

John P. O'Reardon, Kelly C. Allison, Nicole S. Martino, Jennifer D. Lundgren, Moonseong Heo, Albert J. Stunkard

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objective: The authors assessed the efficacy of sertraline in the treatment of night eating syndrome. Method: Thirty-four outpatients diagnosed with night eating syndrome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double-blind, flexible-dose (50-200 mg/day) study. A mixed effects linear regression model was used to analyze change in the primary outcome measure, Clinical Global Impression (CGI) improvement rating. Secondary outcomes included changes in night eating symptoms, the number of nocturnal awakenings and ingestions, total daily caloric intake after the evening meal, CGI severity ratings, quality of life ratings, and weight. Results: Sertraline was associated with significantly greater improvement than placebo. Twelve subjects in the sertraline group (71%) were classified as having responded (CGI improvement rating ≤2, indicating much or very much improved) versus only three (18%) in the placebo group. There were also significant improvements in night eating symptoms, CGI severity ratings, quality of life ratings, frequency of nocturnal ingestions and awakenings, and caloric intake after the evening meal. Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of weight by week 8 (mean=-2.9 kg, SD=3.8) compared with overweight and obese subjects receiving placebo (N=14) (mean=-0.3 kg, SD=2.7). Conclusions: In this 8-week trial, sertraline was effective in the treatment of night eating syndrome and was well tolerated.

Original languageEnglish (US)
Pages (from-to)893-898
Number of pages6
JournalAmerican Journal of Psychiatry
Volume163
Issue number5
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Sertraline
Randomized Controlled Trials
Eating
Placebos
Energy Intake
Therapeutics
Meals
Linear Models
Quality of Life
Weights and Measures
Outpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. / O'Reardon, John P.; Allison, Kelly C.; Martino, Nicole S.; Lundgren, Jennifer D.; Heo, Moonseong; Stunkard, Albert J.

In: American Journal of Psychiatry, Vol. 163, No. 5, 01.01.2006, p. 893-898.

Research output: Contribution to journalArticle

O'Reardon, John P. ; Allison, Kelly C. ; Martino, Nicole S. ; Lundgren, Jennifer D. ; Heo, Moonseong ; Stunkard, Albert J. / A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 5. pp. 893-898.
@article{5b7579fe788b4315b31eace7d3fd3077,
title = "A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome",
abstract = "Objective: The authors assessed the efficacy of sertraline in the treatment of night eating syndrome. Method: Thirty-four outpatients diagnosed with night eating syndrome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double-blind, flexible-dose (50-200 mg/day) study. A mixed effects linear regression model was used to analyze change in the primary outcome measure, Clinical Global Impression (CGI) improvement rating. Secondary outcomes included changes in night eating symptoms, the number of nocturnal awakenings and ingestions, total daily caloric intake after the evening meal, CGI severity ratings, quality of life ratings, and weight. Results: Sertraline was associated with significantly greater improvement than placebo. Twelve subjects in the sertraline group (71{\%}) were classified as having responded (CGI improvement rating ≤2, indicating much or very much improved) versus only three (18{\%}) in the placebo group. There were also significant improvements in night eating symptoms, CGI severity ratings, quality of life ratings, frequency of nocturnal ingestions and awakenings, and caloric intake after the evening meal. Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of weight by week 8 (mean=-2.9 kg, SD=3.8) compared with overweight and obese subjects receiving placebo (N=14) (mean=-0.3 kg, SD=2.7). Conclusions: In this 8-week trial, sertraline was effective in the treatment of night eating syndrome and was well tolerated.",
author = "O'Reardon, {John P.} and Allison, {Kelly C.} and Martino, {Nicole S.} and Lundgren, {Jennifer D.} and Moonseong Heo and Stunkard, {Albert J.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1176/ajp.2006.163.5.893",
language = "English (US)",
volume = "163",
pages = "893--898",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "5",

}

TY - JOUR

T1 - A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome

AU - O'Reardon, John P.

AU - Allison, Kelly C.

AU - Martino, Nicole S.

AU - Lundgren, Jennifer D.

AU - Heo, Moonseong

AU - Stunkard, Albert J.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Objective: The authors assessed the efficacy of sertraline in the treatment of night eating syndrome. Method: Thirty-four outpatients diagnosed with night eating syndrome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double-blind, flexible-dose (50-200 mg/day) study. A mixed effects linear regression model was used to analyze change in the primary outcome measure, Clinical Global Impression (CGI) improvement rating. Secondary outcomes included changes in night eating symptoms, the number of nocturnal awakenings and ingestions, total daily caloric intake after the evening meal, CGI severity ratings, quality of life ratings, and weight. Results: Sertraline was associated with significantly greater improvement than placebo. Twelve subjects in the sertraline group (71%) were classified as having responded (CGI improvement rating ≤2, indicating much or very much improved) versus only three (18%) in the placebo group. There were also significant improvements in night eating symptoms, CGI severity ratings, quality of life ratings, frequency of nocturnal ingestions and awakenings, and caloric intake after the evening meal. Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of weight by week 8 (mean=-2.9 kg, SD=3.8) compared with overweight and obese subjects receiving placebo (N=14) (mean=-0.3 kg, SD=2.7). Conclusions: In this 8-week trial, sertraline was effective in the treatment of night eating syndrome and was well tolerated.

AB - Objective: The authors assessed the efficacy of sertraline in the treatment of night eating syndrome. Method: Thirty-four outpatients diagnosed with night eating syndrome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double-blind, flexible-dose (50-200 mg/day) study. A mixed effects linear regression model was used to analyze change in the primary outcome measure, Clinical Global Impression (CGI) improvement rating. Secondary outcomes included changes in night eating symptoms, the number of nocturnal awakenings and ingestions, total daily caloric intake after the evening meal, CGI severity ratings, quality of life ratings, and weight. Results: Sertraline was associated with significantly greater improvement than placebo. Twelve subjects in the sertraline group (71%) were classified as having responded (CGI improvement rating ≤2, indicating much or very much improved) versus only three (18%) in the placebo group. There were also significant improvements in night eating symptoms, CGI severity ratings, quality of life ratings, frequency of nocturnal ingestions and awakenings, and caloric intake after the evening meal. Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of weight by week 8 (mean=-2.9 kg, SD=3.8) compared with overweight and obese subjects receiving placebo (N=14) (mean=-0.3 kg, SD=2.7). Conclusions: In this 8-week trial, sertraline was effective in the treatment of night eating syndrome and was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=85047699811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047699811&partnerID=8YFLogxK

U2 - 10.1176/ajp.2006.163.5.893

DO - 10.1176/ajp.2006.163.5.893

M3 - Article

VL - 163

SP - 893

EP - 898

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 5

ER -